Benitec Biopharma (NASDAQ:BNTC) Now Covered by Analysts at SVB Leerink

SVB Leerink started coverage on shares of Benitec Biopharma (NASDAQ:BNTC) in a research note issued to investors on Monday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $13.00 target price on the biotechnology company’s stock.

BNTC has been the subject of a number of other research reports. Piper Sandler initiated coverage on shares of Benitec Biopharma in a research report on Thursday, June 13th. They issued an overweight rating and a $30.00 target price for the company. JMP Securities increased their price objective on shares of Benitec Biopharma from $10.00 to $16.00 and gave the stock a market outperform rating in a research note on Monday, April 22nd.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock opened at $9.13 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.18 and a quick ratio of 4.18. The firm has a market cap of $85.55 million, a price-to-earnings ratio of -4.91 and a beta of 0.91. The stock’s 50-day moving average is $8.36 and its 200-day moving average is $6.16. Benitec Biopharma has a one year low of $1.86 and a one year high of $10.88.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter. Equities analysts predict that Benitec Biopharma will post -6.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Benitec Biopharma

An institutional investor recently raised its position in Benitec Biopharma stock. GAMMA Investing LLC increased its position in shares of Benitec Biopharma Inc. (NASDAQ:BNTC) by 53.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,438 shares of the biotechnology company’s stock after buying an additional 1,884 shares during the period. GAMMA Investing LLC owned 0.06% of Benitec Biopharma worth $38,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.